CytomX Therapeutics Raises $41M
San Francisco-based CytomX Therapeutics, a developer of antibody therapeutics, said Tuesday that it has raised $41M in an expanded, Series B financing round. The round was led by Canaan Partners, and also included Third Rock Ventures and the Roche Venture Fund. The company said that Canaan's Tim Shannon joins its board. Cytomx is aiming its monoclonal antibodies at oncology, inflammation, and other areas. $30M of the Series B funding was received by the firm back in 2010.
posted on Wednesday, August 1, 2012 (Link to more information)
Related companies:
CYTOMX THERAPEUTICS LLC
Related stories:
> CytomX Finds $20M More
> CytomX Gets $30M
> Cytomx Sees Pop In IPO
> Arete Therapeutics Raises $35M
> Nuon Therapeutics Raises $27M
silicontap.com Home